News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

Supervisory Board of Epigenomics AG appoints Gregory Hamilton as Chief Executive Officer (CEO)

PDF Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Supervisory Board of Epigenomics AG appoints Gregory Hamilton as Chief Executive Officer (CEO) Berlin, Germany, June 30, 2016 – The Supervisory Board of Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX, ISIN: DE0000A11QW50) has today appointed Gregory Hamilton as Chief Executive Officer with […]

Read more

Epigenomics AG issues new shares by way of private placement

PDF Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Epigenomics AG issues new shares by way of private placement Not for distribution in the United States of America Berlin, Germany, May 24, 2016 – Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX, ISIN: DE0000A11QW50), announces that the Company is raising around EUR 6.8 million […]

Read more

Epigenomics enters strategic license and development agreement with BioChain on novel, blood-based lung cancer test for China

PDF 202 KB   Berlin, Germany, March 30, 2016 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) announces that it has entered a strategic license agreement with BioChain on the development and commercialization of a novel, blood-based lung cancer test for China. BioChain will initiate a clinical trial to validate the lung cancer […]

Read more

Epigenomics receives FDA notification about status of pending approval decision for Epi proColon®

Ad hoc Releases 2016 Pursuant to § 15 WpHG (German Securities Trading Act) PDF 153 KB   Epigenomics receives FDA notification about status of pending approval decision for Epi proColon® Berlin, Germany, January 8, 2016 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) the German-American cancer molecular diagnostics company, today announced that […]

Read more

Epigenomics AG appeals recent FDA request for additional information

Ad hoc Releases 2016 Pursuant to § 15 WpHG (German Securities Trading Act) PDF 154 KB Epigenomics AG appeals recent FDA request for additional information Berlin, Germany, November 25, 2015 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) the German-American cancer molecular diagnostics company, today announced that after discussions with FDA in […]

Read more

Epigenomics adjusts 2015 outlook after FDA response letter

Ad hoc Releases 2016 Pursuant to § 15 WpHG (German Securities Trading Act) PDF 74 KB Berlin, Germany, November 4, 2015 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) adjusts its financial outlook for fiscal year 2015 following the FDA response letter on the Company’s lead product Epi proColon®. As communicated in […]

Read more